PATENT CLAIM ANALYSIS

Application Number: 15925384
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["544", "333000"]

Abstract:
There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.

Claim (Index 23):
A dry powder pharmaceutical formulation according to  claim 17 , wherein the phenyl of R 3  either has hydrogen in the para position or when it bears a substituent in the para position said substituent is selected from methyl, hydroxyl, methoxy, fluoro or chloro.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 90.0
- Lexical Diversity: 1.44737
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15636730', '15259505', '14349356', '14424361', '14422158']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8245816021670557
- 35 USC 102 Novelty (BERT): 0.6252622561614661
- Combined Prediction Score: 0.8046496675664967
- Mean Citation Score: 528.878104
- Max Citation Score: 570.8096
- Similarity Product: 540.025745011139

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test